FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.

• Status: RECRUITING
• Trial end date: 2029-04-01

Summary

The aim of this study is to evaluate the efficacy of the addition of Atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with pMMR and Immunoscore IC-high metastatic colorectal cancer in terms of Progression Free Survival (PFS).

• Phase: PHASE3

Details

• Lead Sponsor: Gruppo Oncologico del Nord-Ovest
• Collaborator: Hoffmann-La Roche
• Treatments: atezolizumab; Bevacizumab; Fluorouracil; Irinotecan; Leucovorin; Oxaliplatin